Jeanny B. Aragon-Ching, MD, FACP
Jeanny B. Aragon-Ching, M.D., F.A.C.P. serves as the Clinical Program Director of Genitourinary Cancers at the Inova Schar Cancer Institute in Fairfax, Virginia, with a joint academic appointment as Associate Professor of Medicine at the University of Virginia. She completed an internship and residency at the Albert Einstein Medical Center in Philadelphia, Pennsylvania where she served the final year as Chief Resident. She later completed a Medical Oncology Fellowship at the National Cancer Institute, National Institutes of Health, in Bethesda, Maryland, where she served as an Associate Investigator on varying trials involved with pharmacogenomics, and early drug discovery for genitourinary tumors. Dr. Aragon-Ching later moved to the George Washington University Medical Center in 2008 and was promoted to the rank of Associate Professor of Medicine in 2014. Her early research work focused on the use of angiogenesis inhibitors, bone-targeted agents, clinical trial design, and drug development. She has served in varying capacities as a peer reviewer, editorial board member, and expert panel for highly acclaimed journals and congressionally directed research program grants. She is a well-published author and investigator of multiple bladder cancer trials, educator and serves on the Editorial Board of various academic journals. Dr. Aragon-Ching has chaired national meetings at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium and has delivered esteemed presentations at the Society of Urologic Oncology, Best of ASCO, and the ASCO Annual Meeting.
She was recruited to Inova Schar Cancer Institute in 2015 to spearhead the GU Oncology program and bring together multidisciplinary expertise and advancement of research, clinical trial development, and personalized clinical care of patients with GU cancers. She has since served in the ASCO GU Program Planning Committee from 2017 – 2019, served as Track Chair for Urothelial cancers in 2018. She has chaired different sessions on bladder urothelial and non-urothelial cancers. She also served in the ASCO Cancer Education Committee for the Annual Meeting for the GU non-prostate cancers. She is dedicated to the research and clinical care of patients with genitourinary cancers and committed to the excellent care and treatment of patients with bladder cancer.
Click here for more information.